Anzeige
Mehr »
Mittwoch, 02.09.2026 - Börsentäglich über 12.000 News
Kupfer sichtbar - doch die entscheidende Antwort kommt jetzt erst noch
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CT5N | ISIN: SE0015988274 | Ticker-Symbol: 5KC
Frankfurt
02.09.26 | 09:55
0,123 Euro
+5,13 % +0,006
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PILA PHARMA AB Chart 1 Jahr
5-Tage-Chart
PILA PHARMA AB 5-Tage-Chart

Aktueller Chart PILA PHARMA Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
PILA PHARMA AB-Investoren interessieren sich auch für diese Wertpapiere
6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & MoreBEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies...
► Artikel lesen
bioAffinity Technologies, Inc. Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced...
► Artikel lesen
WallachBeth Capital LLC: WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million OfferingJERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced...
► Artikel lesen
Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)- LUMUS trial did not meet its primary and secondary endpoints in the overall trial population - - Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high)...
► Artikel lesen
Alumis Inc.: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements- ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO - - Alumis remains on track to submit its New Drug Application...
► Artikel lesen
Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisEnvudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch...
► Artikel lesen
Biotech Stocks At 52-Week Highs - MiniMed Group +10%, Pulse Biosciences, Solventum, Royalty Pharma, Apogee TherapeuticsWASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 1, 2026, as various companies reported financial results and reached certain regulatory milestones.MiniMed...
► Artikel lesen
Biotech Stocks At 52-Week Highs - RenovoRx +15%, Evolus, Crinetics Pharmaceuticals, Apogee TherapeuticsCAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.RenovoRx...
► Artikel lesen
Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline UpdatesAbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive...
► Artikel lesen